176 related articles for article (PubMed ID: 19667285)
1. Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers.
Pham PA; la Porte CJ; Lee LS; van Heeswijk R; Sabo JP; Elgadi MM; Piliero PJ; Barditch-Crovo P; Fuchs E; Flexner C; Cameron DW
Antimicrob Agents Chemother; 2009 Oct; 53(10):4385-92. PubMed ID: 19667285
[TBL] [Abstract][Full Text] [Related]
2. Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers.
Kiser JJ; Gerber JG; Predhomme JA; Wolfe P; Flynn DM; Hoody DW
J Acquir Immune Defic Syndr; 2008 Apr; 47(5):570-8. PubMed ID: 18176327
[TBL] [Abstract][Full Text] [Related]
3. Lack of effect of efavirenz on the pharmacokinetics of tipranavir-ritonavir in healthy volunteers.
la Porte CJ; Sabo JP; Béïque L; Cameron DW
Antimicrob Agents Chemother; 2009 Nov; 53(11):4840-4. PubMed ID: 19721063
[TBL] [Abstract][Full Text] [Related]
4. Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.
Piscitelli S; Kim J; Gould E; Lou Y; White S; de Serres M; Johnson M; Zhou XJ; Pietropaolo K; Mayers D
Br J Clin Pharmacol; 2012 Aug; 74(2):336-45. PubMed ID: 22288567
[TBL] [Abstract][Full Text] [Related]
5. Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin.
Samineni D; Desai PB; Sallans L; Fichtenbaum CJ
J Clin Pharmacol; 2012 Jun; 52(6):922-31. PubMed ID: 21712498
[TBL] [Abstract][Full Text] [Related]
6. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.
Keskitalo JE; Zolk O; Fromm MF; Kurkinen KJ; Neuvonen PJ; Niemi M
Clin Pharmacol Ther; 2009 Aug; 86(2):197-203. PubMed ID: 19474787
[TBL] [Abstract][Full Text] [Related]
7. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.
Pasanen MK; Fredrikson H; Neuvonen PJ; Niemi M
Clin Pharmacol Ther; 2007 Dec; 82(6):726-33. PubMed ID: 17473846
[TBL] [Abstract][Full Text] [Related]
8. Impact of switching treatment from rosuvastatin to atorvastatin on rates of cardiovascular events.
Folse H; Sternhufvud C; Andy Schuetz C; Rengarajan B; Gandhi S
Clin Ther; 2014 Jan; 36(1):58-69. PubMed ID: 24417785
[TBL] [Abstract][Full Text] [Related]
9. Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin.
Foley-Comer AJ; Young AM; Russell-Yarde F; Jordan P
Expert Opin Investig Drugs; 2011 Jan; 20(1):3-12. PubMed ID: 21114416
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design.
Polli JW; Hussey E; Bush M; Generaux G; Smith G; Collins D; McMullen S; Turner N; Nunez DJ
Xenobiotica; 2013 Jun; 43(6):498-508. PubMed ID: 23256625
[TBL] [Abstract][Full Text] [Related]
11. Effect of tipranavir/ritonavir combination on the pharmacokinetics of tadalafil in healthy volunteers.
Garraffo R; Lavrut T; Ferrando S; Durant J; Rouyrre N; MacGregor TR; Sabo JP; Dellamonica P
J Clin Pharmacol; 2011 Jul; 51(7):1071-8. PubMed ID: 21209236
[TBL] [Abstract][Full Text] [Related]
12. Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir.
Mathias AA; Hinkle J; Shen G; Enejosa J; Piliero PJ; Sekar V; Mack R; Tomaka F; Kearney BP
J Acquir Immune Defic Syndr; 2008 Oct; 49(2):156-62. PubMed ID: 18769354
[TBL] [Abstract][Full Text] [Related]
13. Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir.
Song I; Borland J; Chen S; Guta P; Lou Y; Wilfret D; Wajima T; Savina P; Peppercorn A; Castellino S; Wagner D; Hosking L; Mosteller M; Rubio JP; Piscitelli SC
Eur J Clin Pharmacol; 2014 Oct; 70(10):1173-9. PubMed ID: 25146692
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone.
Bruce RD; Altice FL; Moody DE; Lin SN; Fang WB; Sabo JP; Wruck JM; Piliero PJ; Conner C; Andrews L; Friedland GH
Drug Alcohol Depend; 2009 Dec; 105(3):234-9. PubMed ID: 19726139
[TBL] [Abstract][Full Text] [Related]
15. Lack of a pharmacokinetic interaction between steady-state tipranavir/ritonavir and single-dose valacyclovir in healthy volunteers.
Sabo JP; Cong XJ; Kraft MF; Wallace L; Castles MA; Mauss S; MacGregor TR
Eur J Clin Pharmacol; 2011 Mar; 67(3):277-81. PubMed ID: 20963404
[TBL] [Abstract][Full Text] [Related]
16. Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects.
DeGorter MK; Urquhart BL; Gradhand U; Tirona RG; Kim RB
J Clin Pharmacol; 2012 Nov; 52(11):1689-97. PubMed ID: 22167570
[TBL] [Abstract][Full Text] [Related]
17. Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir.
Chen L; Sabo JP; Philip E; Mao Y; Norris SH; MacGregor TR; Wruck JM; Garfinkel S; Castles M; Brinkman A; Valdez H
Antimicrob Agents Chemother; 2007 Jul; 51(7):2436-44. PubMed ID: 17485497
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients.
Goebel FD; MacGregor TR; Sabo JP; Castles M; Johnson PA; Legg D; McCallister S
HIV Clin Trials; 2010; 11(1):28-38. PubMed ID: 20400409
[TBL] [Abstract][Full Text] [Related]
19. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
Mazza F; Stefanutti C; Di Giacomo S; Vivenzio A; Fraone N; Mazzarella B; Bucci A
Am J Cardiovasc Drugs; 2008; 8(4):265-70. PubMed ID: 18690760
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51).
Walmsley SL; Katlama C; Lazzarin A; Arestéh K; Pierone G; Blick G; Johnson M; Meier U; MacGregor TR; Leith JG
J Acquir Immune Defic Syndr; 2008 Apr; 47(4):429-40. PubMed ID: 18176328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
